Abstract: Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide-diluted peptide composition; and sensitizing mononuclear cells with an immunodominant-peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.

Abstract: The invention relates to pharmaceutical compositions that contain viral peptide specific cytotoxic T cells (CTLs), methods for producing viral peptide specific CTLs, and to methods for treating or preventing viral infection.

Abstract: Systems and methods for remotely monitoring hospital patients are provided. Medical devices may capture biometric data associated with a patient positioned in an ICU environment, and a remote display device positioned external to the ICU environment may display an indication of the health of the patient based on the captured biometric data. The indication of the health of the patient may include a graph mapping normalized health statuses associated with the patient over time. Each normalized health status may be based on normalizing a particular type of biometric data based on a medical protocol, so each data point of the graph includes an indication of a normalized health status associated with the patient at a given time. The indication of the health of the patient may include an animated three-dimensional that is dynamically updated to reflect biometric data associated with the patient captured at a time selected by a user.

Abstract: The invention relates to pharmaceutical compositions that contain viral peptide specific cytotoxic T cells (CTLs), methods for producing viral peptide specific CTLs, and to methods for treating or preventing viral infection.

Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.